Browsing: HER2Positive

During the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, an Around the Practice program occurred hosted by CancerNetwork®…

The second clinical scenario involves a 67-year-old patient with HER2-positive metastatic breast cancer receiving T-DXd (presumably with pertuzumab) for 11…

Dr. Rao acknowledges encouraging patient-reported outcomes data from clinical trials while noting potential differences between trial populations and real-world patients.…

Dr. Kruse presents approach to a 54-year-old patient with de novo HER2-positive, hormone receptor-positive metastatic breast cancer involving visceral organs…

Dr. Kruse addresses the balance between efficacy and quality of life when using T-DXd in earlier treatment lines and prolonged…

Dr. Rao outlines specific practical strategies for ILD monitoring, emphasizing high-resolution chest CT scans as the optimal detection method. Standard…

Dr. Kruse discusses evolving perspectives on patient selection for T-DXd-based therapy, noting significant changes in her approach over the past…

Dr. Rao addresses the significant challenge of CNS metastases in HER2-positive metastatic breast cancer, noting that most of her sickest…

Dr. Ami Shah introduces the CancerNetwork Around the Practice program focusing on evolving clinical perspectives in HER2-positive breast cancer, joined…

Dr. Kruse characterizes the ASCO 2026 presentations as a refinement period for implementing clearly positive Phase 3 trial results into…